Baricitinib is an oral, specific, and reversible JAK1 and JAK2 inhibitor authorized for the management of rheumatoid arthritis, atopic dermatitis, and severe alopecia areata in many countries14,15. This evidence concerns the gene JAK1 and rheumatoid arthritis.